Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J H Friedman

Showing results (71-80 of 162) with videos related to

Pageof 17
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|June 8, 2001
Permanent cerebellar toxicity of cytosine arabinoside (Ara C) in a young womanJ H Friedman, N Shetty
Movement Disorders : Official Journal of the Movement Disorder Society|March 1, 1996
Delayed-onset dystonia secondary to unilateral schizencephalyJ H Friedman, W Stone
Movement Disorders : Official Journal of the Movement Disorder Society|January 26, 1999
Cervical stenosis and dystonic cerebral palsyM Rosenfeld, J H Friedman
Movement Disorders : Official Journal of the Movement Disorder Society|August 6, 1999
Carvedilol-induced myoclonusH H Fernandez, J H Friedman
The Journal of Neuropsychiatry and Clinical Neurosciences|November 14, 1998
Should risperidone be used in Parkinson's disease?J H Friedman, B R Ott
Movement Disorders : Official Journal of the Movement Disorder Society|January 26, 1999
Catatonia responsive to lorazepam: a case reportM J Rosenfeld, J H Friedman
The American Journal of Medicine|August 1, 1990
Rostral basilar reversible ischemic neurologic deficit in an HIV-infected patient with cryptococcal meningitisR D Rafal, J H Friedman
Neurology|April 1, 1998
Yawning as an aura for an L-dopa-induced "on" in Parkinson's diseaseJ L Goren, J H Friedman
Neurology|September 1, 1987
Limb dystonia in progressive supranuclear palsyR D Rafal, J H Friedman
Clinical Neuropharmacology|June 1, 1989
An open trial of controlled release carbidopa/L-dopa (sinemet CR) for the treatment of mild-to-moderate Parkinson's diseaseJ H Friedman, M C Lannon
Pageof 17

Showing results (71-80 of 162) with videos related to

Sort By:
Pageof 17
Movement Disorders : Official Journal of the Movement Disorder Society|June 8, 2001
Permanent cerebellar toxicity of cytosine arabinoside (Ara C) in a young womanJ H Friedman, N Shetty
Movement Disorders : Official Journal of the Movement Disorder Society|March 1, 1996
Delayed-onset dystonia secondary to unilateral schizencephalyJ H Friedman, W Stone
Movement Disorders : Official Journal of the Movement Disorder Society|January 26, 1999
Cervical stenosis and dystonic cerebral palsyM Rosenfeld, J H Friedman
Movement Disorders : Official Journal of the Movement Disorder Society|August 6, 1999
Carvedilol-induced myoclonusH H Fernandez, J H Friedman
The Journal of Neuropsychiatry and Clinical Neurosciences|November 14, 1998
Should risperidone be used in Parkinson's disease?J H Friedman, B R Ott
Movement Disorders : Official Journal of the Movement Disorder Society|January 26, 1999
Catatonia responsive to lorazepam: a case reportM J Rosenfeld, J H Friedman
The American Journal of Medicine|August 1, 1990
Rostral basilar reversible ischemic neurologic deficit in an HIV-infected patient with cryptococcal meningitisR D Rafal, J H Friedman
Neurology|April 1, 1998
Yawning as an aura for an L-dopa-induced "on" in Parkinson's diseaseJ L Goren, J H Friedman
Neurology|September 1, 1987
Limb dystonia in progressive supranuclear palsyR D Rafal, J H Friedman
Clinical Neuropharmacology|June 1, 1989
An open trial of controlled release carbidopa/L-dopa (sinemet CR) for the treatment of mild-to-moderate Parkinson's diseaseJ H Friedman, M C Lannon
Pageof 17